Asia Deal Watch: Innovent Picks Up Asian Rights To Three Clinical Cancer Candidates From Incyte

 
• By Ian Haydock, Joseph Haas, and Jung Won Shin

Incyte gets $40m up front and can earn up to $351.5m in milestones pegged to a Phase III JAK1 inhibitor and a pair of Phase II candidates. Shionogi obtains Asian rights to an allosteric inhibitor for cognitive disorders from Tetra.

DealWatch_1200x675

More from Focus On Asia

More from Scrip